Page 419 - Read Online

Page 10 of 13 Shamliyan et al. Vessel Plus 2020;4:35 I http://dx.doi.org/10.20517/2574-1209.2020.34

REFERENCES
1. Shamliyan T, Nambiar S, Martin A. PCV63 what’s the cost of hospitalisations due to heart failure with preserved ejection fraction in the
United States? Value Health 2019;22:S552-3.
2. Dhingra A, Garg A, Kaur S, et al. Epidemiology of heart failure with preserved ejection fraction. Curr Heart Fail Rep 2014;11:354-65.
3. Ziaeian B, Heidenreich PA, Xu H, et al. Race/ethnic differences in outcomes among hospitalized medicare patients with heart failure and
preserved ejection fraction. JACC Heart Fail 2017;5:483-93.
4. Bouthoorn S, Valstar GB, Gohar A, et al. The prevalence of left ventricular diastolic dysfunction and heart failure with preserved ejection
fraction in men and women with type 2 diabetes: a systematic review and meta-analysis. Diab Vasc Dis Res 2018;15:477-93.
5. American Diabetes Association Position Statement. Cardiovascular disease and risk management: standards of medical care in
diabetes-2020. Diabetes Care 2020;43:S111-34.
6. American Diabetes Association Position Statement. 12. Older Adults: Standards of Medical Care in Diabetes-2020. Diabetes Care
2020;43:S152-62.
7. Rawshani A, Rawshani A, Franzen S, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med
2017;376:1407-18.
8. Htay T, Soe K, Lopez-Perez A, Doan AH, Romagosa MA, Aung K. Mortality and cardiovascular disease in type 1 and type 2 diabetes.
Curr Cardiol Rep 2019;21:45.
9. Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol 2020;17:559-73.
10. Oktay AA, Rich JD, Shah SJ. The emerging epidemic of heart failure with preserved ejection fraction. Curr Heart Fail Rep
2013;10:401-10.
11. Zheng SL, Chan FT, Nabeebaccus AA, et al. Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a
systematic review and meta-analysis. Heart (British Cardiac Society) 2018;104:407-15.
12. Kjeldsen SE, von Lueder TG, Smiseth OA, et al. Medical therapies for heart failure with preserved ejection fraction. Hypertension
2020;75:23-32.
13. Gladden JD, Chaanine AH, Redfield MM. Heart failure with preserved ejection fraction. Ann Rev Med 2018;69:65-79.
14. Bonsu KO, Arunmanakul P, Chaiyakunapruk N. Pharmacological treatments for heart failure with preserved ejection fraction-a systematic
review and indirect comparison. Heart Fail Rev 2018;23:147-56.
15. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in
type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet (London, England) 2019;393:31-9.
16. Birkeland KI, Jorgensen ME, Carstensen B, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following
initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational
observational analysis. Lancet Diabetes Endocrinol 2017;5:709-17.
17. Zelniker TA, Braunwald E. Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art
review. J Am Coll Cardiol 2018;72:1845-55.
18. Singh AK, Singh R. Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled
and observational studies. Expert Rev Clin Pharmacol 2019;12:299-308.
19. Lan NSR, Fegan PG, Yeap BB, Dwivedi G. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current
evidence and future directions. ESC Heart Fail 2019;6:927-35.
20. AstraZeneca Pharmaceuticals LP Wilmington D. FARXIGA- dapagliflozin tablet, film coated FDA label. May 2020. Available from:
https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/01f90c94-71cb-4a1f-81ff-8004b850529b/spl-doc?hl=dapagliflozin. [Last accessed on
16 Nov 2020]
21. Boehringer Ingelheim Pharmaceuticals Inc. JARDIANCE- empagliflozin tablet, film coated FDA label. 2014. Available from: https://
nctr-crs.fda.gov/fdalabel/services/spl/set-ids/a77214ca-572e-485e-aae9-f7950187e5fb/spl-doc?hl=empagliflozin. [Last accessed on 16
Nov 2020]
22. Janssen Pharmaceuticals Inc. INVOKANA- canagliflozin tablet, film coated FDA label. March 2013. Available from: https://nctr-crs.fda.
gov/fdalabel/services/spl/set-ids/b9057d3b-b104-4f09-8a61-c61ef9d4a3f3/spl-doc?hl=canagliflozin. [Last accessed on 16 Nov 2020]
23. Fitchett D, Inzucchi SE, Cannon CP, et al. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of
cardiovascular risk in the EMPA-REG outcome trial. Circulation 2019;139:1384-95.
24. Radholm K, Figtree G, Perkovic V, et al. Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program.
Circulation 2018;138:458-68.
25. Dewan P, Solomon SD, Jhund PS, et al. Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular
ejection fraction in DAPA-HF. Eur J Heart Fail 2020;22:1247-58.
26. Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American heart
association and the heart failure society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart
failure guideline update. Circulation 2019;140:e294-324.
27. Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American heart
association and the heart failure society of America. J Card Fail 2019;25:584-619.
28. Ezekowitz JA, O’Meara E, McDonald MA, et al. 2017 comprehensive update of the canadian cardiovascular society guidelines for the
management of heart failure. Can J Cardiol 2017;33:1342-433.
29. O’Meara E, McDonald M, Chan M, et al. CCS/CHFS heart failure guidelines: clinical trial update on functional mitral regurgitation,